Wednesday, 18 September, 2024
|
In Stepanakert:   +12 °C

#AstraZeneca for the first time admits its Covishield vaccine may lead to rare side effect

#AstraZeneca for the first time admits its Covishield vaccine may lead to rare side effect
16148
Tuesday, 30 April, 2024, 23:24

AstraZeneca has admitted for the first time in court documents that its Covid-19 vaccine, sold globally under the brand names Covishield and Vaxzevria among others, may lead to a rare side-effect.

Covishield can cause, in rare cases, a condition that leads to blood clots and low platelet count, the vaccine-maker has said in court documents. This condition is known as Thrombosis with Thrombocytopenia Syndrome (TTS).

Covishield was produced by the Serum Institute of India and widely administered in the country. AstraZeneca is facing a class action lawsuit in the UK over claims that its vaccine caused deaths and severe injuries in several cases.